Core Insights - The "Qihang·2025 Financial Summit" was successfully held in Beijing, focusing on "New Starting Point, New Momentum, New Journey," gathering leaders and guests from various sectors including regulatory bodies, industry associations, financial institutions, and media [1] - The 14th "Golden Wisdom Award" results were announced, with Tianshili winning the "Excellence Award in the Pharmaceutical and Biological Industry" [2] Group 1: Award Significance - The "Golden Wisdom Award" aims to establish benchmarks for high-quality development, guiding listed companies to focus on their core businesses, innovate continuously, and fulfill social responsibilities [3] - The award reflects the industry's recognition of Tianshili's core competitiveness and high-quality development achievements, emphasizing its commitment to innovation and industry leadership [4] Group 2: Financial Performance - In the first three quarters of 2025, Tianshili achieved pharmaceutical industrial revenue of 5.709 billion yuan, maintaining a steady growth trend [4] - The net profit attributable to shareholders reached 984 million yuan, representing a year-on-year increase of 16.88%, indicating a steady improvement in profitability [4] Group 3: Innovation and R&D - Tianshili's innovation is a core driver of its high-quality development, with a dual-engine R&D system for innovative traditional Chinese medicine and biopharmaceuticals now entering a phase of significant results [4] - The company has 31 innovative drugs in its pipeline, with nearly 20 traditional Chinese medicines in late clinical stages, showcasing its long-term innovation potential [5] Group 4: Future Outlook - The award signifies industry confidence in Tianshili's "dual-engine" innovation strategy and future growth prospects [6] - Tianshili plans to deepen its investment in innovation, accelerate the conversion of pipeline results, and optimize its core business layout to contribute to public health and the upgrade of the biopharmaceutical industry [6]

Core Viewpoint - The "Qihang·2025 Financial Summit" held in Beijing recognized Tianjin Tianshili as the winner of the "Excellence Award in the Pharmaceutical and Biological Industry," highlighting its achievements in high-quality development and innovation in the pharmaceutical sector [1][4]. Group 1: Award and Recognition - The "Jinzhi Award" aims to set benchmarks for high-quality development, guiding listed companies to focus on their core businesses and innovate continuously [3]. - The award recognizes companies that lead high-quality development in the pharmaceutical and biological industry, emphasizing innovation, clinical value transformation, and health security [3][4]. - Tianjin Tianshili's receipt of the award reflects industry acknowledgment of its core competitiveness and high-quality development results [4][6]. Group 2: Financial Performance - In the first three quarters of 2025, Tianjin Tianshili achieved pharmaceutical industrial revenue of 5.709 billion yuan, maintaining a steady growth trend [4]. - The net profit attributable to shareholders reached 984 million yuan, representing a year-on-year increase of 16.88%, indicating improved profitability [4]. Group 3: Innovation and R&D - Innovation is the core driving force behind Tianjin Tianshili's high-quality development, with a focus on building a dual-engine R&D system for innovative traditional Chinese medicine and biopharmaceuticals [4][5]. - The company has 31 innovative drugs in its pipeline, with nearly 20 traditional Chinese medicines in late clinical stages, showcasing its long-term innovation potential [5]. - Key products include a PD-L1/VEGF dual antibody that is undergoing clinical trials, which may lead to breakthroughs in cancer treatment [5]. Group 4: Future Outlook - The award serves as a recognition of past achievements and reinforces confidence in Tianjin Tianshili's dual-engine innovation strategy and future growth prospects [6]. - The company plans to deepen investment in innovation, accelerate the conversion of pipeline results, and optimize its core business layout to contribute to public health and the upgrade of the biopharmaceutical industry [6].

证券代码：600535 证券简称：天士力 编号：临 2025-080 号 天士力医药集团股份有限公司 关于变更公司电子邮箱的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"）根据实际工作需要，对公 司电子邮箱进行变更，具体情况如下： 变更前的公司电子邮箱：stock@tasly.com 变更后的公司电子邮箱：stock@taslypharma.com 除上述变更外，公司办公地址、联系电话等其他联系方式保持不变。变更后的 电子邮箱自本公告披露之日起正式启用，原邮箱地址同步停用，敬请广大投资者注 意。由此给投资者带来的不便，敬请谅解。欢迎广大投资者通过新的电子邮箱与公 司沟通交流。 特此公告。 天士力医药集团股份有限公司董事会 2025 年 12 月 27 日 1 ...

内蒙古建中律师事务所 关于天士力医药集团股份有限公司 2025 年第六次临时股东会的法律意见书 2025 内建中券意字第 28 号 致：天士力医药集团股份有限公司 内蒙古建中律师事务所（以下称"本所"）受天士力医药集团股份有限公司 （以下称"贵公司"或"公司"）的委托，指派本所执业律师刘弘、张辛羽（以 下称"本所经办律师"）出席了贵公司 2025 年第六次临时股东会（以下称"本 次股东会"），并根据《中华人民共和国证券法》（以下称"《证券法》"）、 《中华人民共和国公司法》（以下称"《公司法》"）和中国证监会《上市公司 股东会规则》（以下称"《股东会规则》"）等法律、法规和规范性文件以及《天 士力医药集团股份有限公司章程》（以下称"《章程》"）的规定，就本次股东 会的召集、召开程序、出席会议人员资格以及表决程序和表决结果的合法有效性 出具本法律意见书。 为出具本法律意见书，本所经办律师已对本次股东会所涉及的有关事项及文 件资料进行了必要的核查和验证，且贵公司已对前述资料的真实性和准确性向本 所作了保证。 本法律意见书仅供贵公司为本次股东会的适当目的使用，不得被任何人用于 其他任何目的。 本所同意贵公司将本法律 ...

2025年第六次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 证券代码：600535 证券简称：天士力 编号：临2025-079号 天士力医药集团股份有限公司 一、 会议召开和出席情况 (一) 股东会召开的时间：2025 年 12 月 26 日 (二) 股东会召开的地点：天士力医药集团股份有限公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 566 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 721,099,203 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 50.8084 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议采取现场投票与网络投票相结合的方式召开及表决。会议由公司董事 会召集，根据《公司章程》有关规定，由董事长周辉女士现场主持本次会议。会议 的召集、召开符 ...

Group 1 - The clinical trial for Tianjin Tasly Pharmaceutical Group Co., Ltd.'s allogeneic adipose-derived mesenchymal stem cell injection (B2065) for treating acute ischemic stroke has been initiated, with the trial registration number CTR20255104 and the first public information date set for December 26, 2025 [1] - The drug is administered via intravenous infusion in three dosage groups: 1 bag, 3 bags, and 9 bags, with an infusion time of approximately 20 minutes (±2 minutes) per bag, and the treatment is a single administration [1] - The primary objective of the trial is to evaluate the safety and tolerability of B2065, while secondary objectives include assessing the preliminary clinical efficacy and exploring the mechanism and immunogenicity of B2065 [1] Group 2 - The main endpoints of the trial include the incidence of dose-limiting toxicities (DLT) during the dose escalation phase, adverse events, vital signs, all-cause mortality rates at 14 days, 12 months, and 24 months, and tumor formation observations at 6 months and 24 months [2] - Secondary endpoints consist of the proportion of participants with mRS scores of 0-2 and 0-1 at different time points, the proportion of participants with a decrease in NIHSS score of ≥4 (NIHSS score ≤1), the proportion of participants with BI scores of 95-100, and EQ-5D-5L scores [2] - The current status of the trial is ongoing (not yet recruiting), with a target enrollment of 36 participants [2]

Group 1 - The core point of the article is that Lisheng Pharmaceutical (002393) announced through an interactive platform that its subsidiary, Central Pharmaceutical, holds a 12.15% stake in Tian Shi Li (600535) Biopharmaceutical Industry Group Co., Ltd [1]

2025 年第六次临时股东会会议资料 天士力医药集团股份有限公司 2025 年第六次临时股东会会议资料 2025 年 12 月 26 日 2025 年第六次临时股东会会议资料 天士力医药集团股份有限公司 2025 年第六次临时股东会议程 一、会议时间： 现场会议召开时间：2025 年 12 月 26 日 15 点 30 分 网络投票系统及投票时间： 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2025 年 12 月 26 日 至 2025 年 12 月 26 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东会召 开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平台的投 票时间为股东会召开当日的 9:15-15:00。 二、会议地点：天津市北辰科技园区天士力现代中药城天士力医药集团股份有限公司会 议室 三、会议议程： （一）宣布会议正式开始 （二）宣布大会出席情况和事项的表决方法 （三）推举表决票检票组成员 （四）宣读议案并请股东针对议案发表意见 | 序号 | 议案名称 | | --- | --- | | ...

Core Insights - Cardiovascular diseases are a significant public health issue in China, impacting the health and safety of the population, necessitating robust prevention and treatment efforts [1] - The "Heart Power: Rewalking the Long March" grassroots cardiovascular disease prevention project has successfully conducted activities across 17 provinces since its launch in 2024, engaging over 140,000 healthcare professionals and providing health services to more than 3,500 individuals [1] Group 1 - The project aims to empower grassroots healthcare through a collaborative approach between traditional Chinese and Western medicine, focusing on safeguarding public heart and brain health [1] - The project has been recognized for its achievements during a summary conference, where experts were awarded for their contributions and a new project plan for 2026 was announced, emphasizing resource integration and innovative models [2] Group 2 - During the event, medical experts from top hospitals conducted multidisciplinary consultations and teaching rounds, offering personalized health assessments and enhancing local medical staff's clinical skills through hands-on training [5] - The conference featured academic exchanges on topics such as hypertension and coronary intervention, fostering deep discussions among experts and local healthcare providers to share best practices [5] Group 3 - The project will continue to integrate resources from healthcare, industry, and academia to enhance grassroots medical service capabilities, contributing to a comprehensive prevention system for cardiovascular diseases [7] - The initiative embodies the spirit of the Long March, focusing on community welfare and addressing health challenges, aligning with the Healthy China strategy that prioritizes grassroots healthcare [7]

Investment Rating - The report maintains a rating of "Buy" for the pharmaceutical and biotechnology sector, with a focus on specific companies such as Innovent Biologics, Efang Biologics, and Mindray Medical [4][27]. Core Insights - The report emphasizes the investment opportunities in the "One Old, One Young" sectors, particularly in reproductive assistance, pediatric drugs and vaccines, maternal and infant health monitoring, and aging-related consumer healthcare [2][24]. - It highlights the importance of clinical value in the pharmaceutical sector, suggesting that future investments should focus on innovative drug chains and high-end medical devices [3][25]. - The report notes that the domestic pharmaceutical sector is experiencing a valuation recovery, driven by supportive policies and increasing global competitiveness [26]. Summary by Sections Market Review - The A-share pharmaceutical index fell by 1.04%, underperforming the CSI 300 index by 0.96 percentage points and the ChiNext index by 2.52 percentage points, ranking 17th among 31 sub-industries [1][15]. - The Hong Kong Hang Seng Medical Health Index decreased by 2.26%, lagging behind the Hang Seng Index by 0.97 percentage points [1][15]. R&D Progress - Recent developments include IND applications from Haisimengnuo and clinical trial advancements for various drugs from companies like Hengrui Medicine and Anke Biotechnology [29][30]. Key Companies and Valuation - The report provides a detailed earnings forecast and valuation table for key companies, indicating a positive outlook for companies like WuXi AppTec and Mindray Medical, with projected PE ratios decreasing over the next few years [4][27]. Policy and Industry Resonance - The report discusses the eight key tasks for medical insurance in 2026, focusing on improving coverage for flexible employment and enhancing maternal healthcare services, which are expected to boost the birth rate and the rehabilitation medical device industry [2][20][24]. Investment Strategy - The report suggests a three-stage investment strategy based on clinical value, recommending investments in innovative drugs and high-value medical devices, with a focus on companies that are expanding internationally [3][25][26].